Choose ALUNBRIG® (brigatinib) For Proven First-Line CNS Efficacy
In an ALTA 1L study post hoc subgroup analysis of patients with brain metastases at baseline, ALUNBRIG demonstrated longer median PFS and higher response rates versus crizotinib.1-3
Brain metastases population (post hoc subgroup analysis)
The Median PFS was Longer with ALUNBRIG vs Crizotinib1,2
PFS in Patients with Any Brain Metastases at Baseline1,2
23% absolute risk reduction: 50% event rate (n=20/40) for patients taking ALUNBRIG vs 73% event rate (n=30/41) for patients taking crizotinib1
Study Limitation: ALTA 1L was not powered to detect differences across subgroups.
Brain metastases populationa (post hoc subgroup analysis)
The Intracranial Response Rate was 3 Times Higher with ALUNBRIG vs crizotinib3
Confirmed Intracranial Overall Response Rates:
Patients with Measurable Brain Metastases at Baseline3
ALUNBRIG
(n=14/18)
28% complete response
(95% CI: 10, 53)
50% partial response
(95% CI: 26, 74)
crizotinib
(n=6/23)
0 complete response
(95% CI: 0, 15)
26% partial response
(95% CI: 10, 48)
BIRC-assessed confirmed intracranial ORR and intracranial DOR according to RECIST v1.1 in the subgroup of 41 patients with measurable brain metastases at baseline.3
64% of responders achieved an intracranial response duration ≥24 monthsb with ALUNBRIG vs NE for crizotinib3
Brain metastases population (post hoc subgroup from final analysis with 40.4 months of median follow-up)
57% Reduction in the Risk of Death vs Crizotinib4
OS in Patients with Measurable Brain Metastases at Baseline4
Study Limitation: ALTA 1L was not powered to detect differences across subgroups.
aPatients with brain metastases ≥10 mm in longest diameter at baseline.
bDuration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of intracranial nontarget lesions) or death.
BIRC, blinded independent review committee; CI, confidence interval; DOR, duration of response; HR, hazard ratio; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.